Sequential Antibody-Drug Conjugate Therapy with Enfortumab Vedotin and Sacituzumab Govitecan in Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis
cslide.ctimeetingtech.com/es…
Sacituzumab Govitecan (SG) Combined With Enfortumab Vedotin (EV) and Zimberelimab (ZIM) in Treatment-Naive Metastatic Urothelial Cancer (mUC): Interim Results From Phase 1b TROPHY-U-01 Cohort 7
cslide.ctimeetingtech.com/es…
Bulumtatug fuvedotin a nectin-4–directed antibody-drug conjugate (ADC), in patients with locally advanced or metastatic TNBC previously treated with topoisomerase I inhibitor (TopI)-based ADCs: Results from a phase 2 study
cslide.ctimeetingtech.com/es…
Paired-biopsy multi-omic analysis reveals target-independent mechanisms of antibody–drug conjugate (ADC) resistance in metastatic breast cancer (MBC)
cslide.ctimeetingtech.com/es…
Elfetabart drozuntecan (Elfe-D; DB-1311/BNT324 [B7H3 ADC]) + pumitamig (PD-L1 x VEGF-A bsAb) in patients with advanced solid tumors: First results from a global phase 2 trial
cslide.ctimeetingtech.com/es…
Impact of ctDNA detected BRCA reversion mutations on outcomes of patients (pts) with BRCA-mutated metastatic breast cancer (mBC) treated with antibody-drug conjugates (ADC)
cslide.ctimeetingtech.com/es…
Exploratory translational analysis of homologous recombination deficiency in tumor samples from the randomized phase III CORAIL study of lurbinectedin versus control in platinum-resistant ovarian cancer
cslide.ctimeetingtech.com/es…
1955RO - Initial results with IMA402 a PRAME-targeted T-cell receptor (TCR)-based bispecific T-cell engager (TCER) in advanced solid tumors
cslide.ctimeetingtech.com/es…
Targeting PRAME+ tumors with IMA203CD8, a PRAME-directed TCR T-cell therapy: Results from a phase 1 study
cslide.ctimeetingtech.com/es…
cslide.ctimeetingtech.com/es…
Pretreatment albumin levels as a predictor of mirvetuximab soravtansine effectiveness in platinum-resistant ovarian cancer (PROC) patients
Cell Polarity Disruption in Indolent RAS-mutated Follicle Cells Primes Aggressive Behaviours in Drosophila and Human Models of Ovarian Cancer
research.unite.it/handle/115…
HISTOTYPE-SPECIFIC ANTIBODY-DRUG CONJUGATE STRATEGIES FOR OVARIAN CANCER: TRANSCRIPTOMIC TARGET IDENTIFICATION AND DRUG EFFLUX CO-EXPRESSION IN CLEAR CELL VS. HIGH-GRADE SEROUS CARCINOMA
cslide.ctimeetingtech.com/ig…
Palbociclibe combinado a letrozol após progressão a quimioterapia de segunda linha para mulheres com câncer de ovário receptor de estrogênio e/ou progesterona positivo
lume.ufrgs.br/handle/10183/3…
Bystander effect in antibody-drug conjugates: Navigating the fine line in tumor heterogeneity
sciencedirect.com/science/ar…
Genome-Wide Assessment of DNA Methylation Fidelity Identifies Representative Ovarian Cancer Cell Line Models
onlinelibrary.wiley.com/doi/…
Antibody-Drug Conjugate Targeting c-Kit for the Treatment of Small Cell Lung Cancer
pmc.ncbi.nlm.nih.gov/article…
A survey method using three indicators (total, regimen, and each line contribution periods) to understand the actual treatment status for patients with recurrent ovarian cancer in real-world clinical practice
researchsquare.com/article/r…
Comparing PI3K/Akt Inhibitors Used in Ovarian Cancer Treatment
frontiersin.org/journals/pha…
Sacituzumab Govitecan overcomes carboplatin resistance in TNBC through enhancing METTL3/METTL14/YTHDF1/PRMT5 axis-mediated ferroptosis
researchsquare.com/article/r…